Search

Your search keyword '"Toapanta-Gaibor, Nestor"' showing total 9 results
Start Over Author "Toapanta-Gaibor, Nestor"
9 results on '"Toapanta-Gaibor, Nestor"'

6. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study

Author

Martin‐Moreno, Paloma L., primary, Sánchez‐Fructuoso, Ana I., additional, Mazuecos, Auxiliadora, additional, Mir, Marisa, additional, Lopez‐Lopez, Isabel, additional, González‐Rinne, Ana, additional, Coca, Armando, additional, Valero, Rosalía, additional, Ventura Galiano, Ana, additional, Ridao, Natalia, additional, Toapanta‐Gaibor, Nestor G., additional, Fernández‐Tagarro, Ernesto, additional, Cruzado‐Vega, Leonidas, additional, Pérez‐Mir, Mónica, additional, and Jiménez, Carlos, additional

Published
2021
Full Text
View/download PDF

8. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.

Author

Jacobs-Cachá, Conxita, Vergara, Ander, García-Carro, Clara, Agraz, Irene, Toapanta-Gaibor, Nestor, Ariceta, Gema, Moreso, Francesc, Serón, Daniel, López-Hellín, Joan, and Soler, Maria José

Subjects
FOCAL segmental glomerulosclerosis, DIAGNOSIS, KIDNEY diseases, CHRONIC kidney failure, BIOMARKERS, KIDNEY transplantation
Abstract

Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Survival of patients >= 70 years with advanced chronic kidney disease: Dialysis vs. conservative care

Author

Martinez Echevers, Yeleine, Toapanta Gaibor, Nestor Gabriel, Nava Perez, Nathasha, Barbosa Martin, Francisco, Montes Delgado, Rafael, Guerrero Riscos, Maria Angeles, [Martinez Echevers, Yeleine] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain, [Toapanta Gaibor, Nestor Gabriel] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain, [Nava Perez, Nathasha] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain, [Barbosa Martin, Francisco] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain, [Montes Delgado, Rafael] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain, and [Guerrero Riscos, Maria Angeles] Hosp Univ Virgen Rocio, UGC Nefrol Urol, Seville, Spain

Subjects
Stage, Elderly, Advanced chronic kidney disease, Survival, Prevention, Population, Elderly-patients, Frail patient, Initiation, Outcomes, Conservative care, Management
Abstract

Introduction: The number of elderly patients with advanced chronic kidney disease (ACKD) has increased in recent years, and the best therapeutic approach has not been determined due to a lack of evidence.Objectives: To observe the progression of elderly patients with ACKD (stages 4 and 5) and to compare the survival of stage 5 CKD patients with and without dialysis treatment.Material and methods: All patients >= 70 years who began ACKD follow-up from 01/01/2007 to 31/12/2008 were included, and their progression was observed until 31/12/2013. Demographic data, the Charlson comorbidity index, history of ischaemic heart disease (IHD) and diabetes mellitus (DM) were assessed.Results: A total of 314 patients >= 70 years with stages 4 and 5 CKD were studied. Of these patients, 162 patients had stage 5 CKD at the beginning of follow-up or progressed to stage 5 during the study, and 69 of these patients were treated with dialysis. In the stage 5 group: median age was 77 years (74-81); 48% had IHD; 50% had DM, Charlson 7 (6-9). Kaplan-Meier survival analysis: >= 70 years (93 vs. 69 patients with dialysis, log rank: 15 P= 70 years who began ACKD follow-up from 01/01/2007 to 31/12/2008 were included, and their progression was observed until 31/12/2013. Demographic data, the Charlson comorbidity index, history of ischaemic heart disease (IHD) and diabetes mellitus (DM) were assessed.Results: A total of 314 patients >= 70 years with stages 4 and 5 CKD were studied. Of these patients, 162 patients had stage 5 CKD at the beginning of follow-up or progressed to stage 5 during the study, and 69 of these patients were treated with dialysis. In the stage 5 group: median age was 77 years (74-81); 48% had IHD; 50% had DM, Charlson 7 (6-9). Kaplan-Meier survival analysis: >= 70 years (93 vs. 69 patients with dialysis, log rank: 15 P= 70 years with stages 4 and 5 CKD were studied. Of these patients, 162 patients had stage 5 CKD at the beginning of follow-up or progressed to stage 5 during the study, and 69 of these patients were treated with dialysis. In the stage 5 group: median age was 77 years (74-81); 48% had IHD; 50% had DM, Charlson 7 (6-9). Kaplan-Meier survival analysis: >= 70 years (93 vs. 69 patients with dialysis, log rank: 15 P= 70 years (93 vs. 69 patients with dialysis, log rank: 15 P= 75 years (74 vs. 46 patients with dialysis, log rank: 8.9 P=.003); patients >= 80 (40 vs. 15 patients with dialysis) and p=0,2. Patients receiving dialysis were younger, with a lower Charlson comorbidity index and shorter follow-up time.Conclusions: Our study shows that dialysis treatment improves survival, although this benefit is lost in patients >= 80 years. (C) 2016 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results